Big Moving Stock keep track of the biggest moving stocks in the market.


Nasdaq: GOOG NFLX AMZN BIIB TSLA ILMN WYNN CHTR AMGN GMCR COST SIAL CNQR SBAC AAPL VRTX MDVN CELG SSYS
Nyse: ACT V LNKD AGN IVV GS LMT SPG FDX PXD IBM MMM TWC CMI APD GD NOC HUM BA BDX
New Highs: BLK ACT V IVV WHR RL ORLY CHTR BWLD APD NOC HUM BDX PH FFIV TMO EW UNP PANW SBAC

The Hot Industries

Business Software & Services 1
Industrial Equipment & Components 1
Medical Instruments & Supplies 1

The Hot Sectors

Healthcare 5
Services 5
Industrial Goods 2

ARIA Stock Chart


ARIA
Analyze

Sector:

Healthcare
Daily

Industry:

Biotechnology
Weekly

Employees:

307
Monthly

Website:

http://www.ariad.com

ARIA Ariad Pharmaceuticals Inc.

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.

favicon

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape

25 Nov 2014, 9:31 amAriad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7% - Tale of the Tape
favicon

Ariad Pharmaceuticals (ARIA) Jumps: Stock Gains 9.7%

25 Nov 2014, 5:52 amAriad Pharmaceuticals (ARIA) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
favicon

Equity Coverage on Biotech Industry - Gilead Sciences, MannKind, ARIAD Pharma, iBio Inc., and Celgene

14 Nov 2014, 7:27 amLONDON, November 14, 2014 /PRNewswire/ -- Investor-Edge has initiated coverage on the following equities: Gilead Sciences Inc. (NASDAQ: GILD), MannKind Corporation (NASDAQ: MNKD), ARIAD Pharmaceuticals Inc. (NASDAQ: ARIA), iBio Inc. (NYSE MKT: IBIO), and Celgene Corporation (NASDAQ:...
favicon

'Mad Money' Lightning Round: A Group to Avoid

14 Nov 2014, 4:41 amSearch Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here's what Jim Cramer had to say about some of the stocks callers offered up during the Mad Money Lightning Round Thursday evening: Must Read: Warren Buffett's Top 10 Dividend Stocks Autodesk : "That was a great quarter but I think we missed it. Let's wait for a ...
favicon

Chet Faker keeps it real

10 Nov 2014, 6:53 pmElectro-soul crooner Chet Faker tries not to think about how far he’s come in a golden year.
favicon

Ariad tops 3Q profit forecasts

5 Nov 2014, 5:57 amOn a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 27 cents. The results topped Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment ...
favicon

Will ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog

4 Nov 2014, 4:26 pmWill ARIAD (ARIA) Miss This Earnings Season? - Analyst Blog
favicon

Will ARIAD (ARIA) Miss This Earnings Season?

4 Nov 2014, 2:00 pmARIAD Pharmaceuticals, Inc. (ARIA) has Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
favicon

Commit To Buy ARIAD Pharmaceuticals At $3.50, Earn 17.1% Using Options

27 Oct 2014, 10:12 amInvestors considering a purchase of ARIAD Pharmaceuticals, Inc. (NASD: ARIA) shares, but cautious about paying the going market price of $5.63/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2016 put at the $3.50 strike, which has a bid at the time of this writing of 60 cents ...
favicon

Ariad Pharma: Will It Return To Its Heyday?

27 Oct 2014, 7:50 amShares of Ariad Pharmaceuticals Inc. (ARIA) have gained more than 60 percent in the last one year, and it looks like the company is slowly getting back in the game. Here's the story of the fall and recovery of Ariad...